Jana Heringer1, Vassili Valayannopoulos2, Allan M Lund3, Frits A Wijburg4, Peter Freisinger5, Ivo Barić6, Matthias R Baumgartner7, Peter Burgard1, Alberto B Burlina8, Kimberly A Chapman9, Elisenda Cortès I Saladelafont10, Daniela Karall11, Chris Mühlhausen12, Victoria Riches13, Manuel Schiff14, Jolanta Sykut-Cegielska15, John H Walter16, Jiri Zeman17, Brigitte Chabrol18, Stefan Kölker19. 1. Department of General Pediatrics, Division of Neuropediatrics and Inherited Metabolic Diseases, University Children's Hospital Heidelberg, Im Neuenheimer Feld 430, D-69120, Heidelberg, Germany. 2. Assistance Publique-Hôpitaux de Paris, Centre de Référence de Maladies Métaboliques (MaMEA), Hôpital Universitaire Necker-Enfants Malades and Insitut MAGINE, Paris, France. 3. Centre for Inherited Metabolic Diseases, Department of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. 4. Department of Pediatrics, Academic Medical Center, Amsterdam, Netherlands. 5. Klinikum am Steinenberg, Klinik für Kinder- und Jugendmedizin, Reutlingen, Germany. 6. School of Medicine, University Hospital Center Zagreb and University of Zagreb, Zagreb, Croatia. 7. Division of Metabolism and Children's Research Centre, University Children's Hospital Zurich, Steinwiesstraße 75, CH-8032, Zurich, Switzerland. 8. U.O.C. Malattie Metaboliche Ereditarie, Azienda Ospedaliera di Padova, Padova, Italy. 9. Children's National Medical Center, 111 Michigan Avenue, N.W., Washington, DC, 20010, USA. 10. Hospital San Joan de Deu, Servicio de Neurologia and CIBERER, ISCIII, Barcelona, Spain. 11. Clinic for Pediatrics I, Inherited Metabolic Disorders, Medical University of Innsbruck, Innsbruck, Austria. 12. Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany. 13. Birmingham Children's Hospital NHS Foundation Trust, Birmingham, UK. 14. Reference Center for Inborn Errors of Metabolism, APHP, University Paris-Diderot and INSERM U1141, Robert-Debré Hospital, Paris, France. 15. Screening Department, Institute of Mother and Child, Warsaw, Poland. 16. Willink Biochemical Genetics Unit, Genetic Medicine, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK. 17. First Faculty of Medicine, Charles University and General University of Prague, Prague, Czech Republic. 18. Centre de Référence des Maladies Héréditaires du Métabolisme, Service de Neurologie, Hôpital d'Enfants, CHU Timone, Marseilles, France. 19. Department of General Pediatrics, Division of Neuropediatrics and Inherited Metabolic Diseases, University Children's Hospital Heidelberg, Im Neuenheimer Feld 430, D-69120, Heidelberg, Germany. Stefan.Koelker@med.uni-heidelberg.de.
Abstract
BACKGROUND AND AIM: To describe current diagnostic and therapeutic strategies in organic acidurias (OADs) and to evaluate their impact on the disease course allowing harmonisation. METHODS: Datasets of 567 OAD patients from the E-IMD registry were analysed. The sample includes patients with methylmalonic (MMA, n = 164), propionic (PA, n = 144) and isovaleric aciduria (IVA, n = 83), and glutaric aciduria type 1 (GA1, n = 176). Statistical analysis included description and recursive partitioning of diagnostic and therapeutic strategies, and odds ratios (OR) for health outcome parameters. For some analyses, symptomatic patients were divided into those presenting with first symptoms during (i.e. early onset, EO) or after the newborn period (i.e. late onset, LO). RESULTS: Patients identified by newborn screening (NBS) had a significantly lower median age of diagnosis (8 days) compared to the LO group (363 days, p < 0.001], but not compared to the EO group. Of all OAD patients 71 % remained asymptomatic until day 8. Patients with cobalamin-nonresponsive MMA (MMA-Cbl(-)) and GA1 identified by NBS were less likely to have movement disorders than those diagnosed by selective screening (MMA-Cbl(-): 10 % versus 39 %, p = 0.002; GA1: 26 % versus 73 %, p < 0.001). For other OADs, the clinical benefit of NBS was less clear. Reported age-adjusted intake of natural protein and calories was significantly higher in LO patients than in EO patients reflecting different disease severities. Variable drug combinations, ranging from 12 in MMA-Cbl(-) to two in isovaleric aciduria, were used for maintenance treatment. The effects of specific metabolic treatment strategies on the health outcomes remain unclear because of the strong influences of age at onset (EO versus LO), diagnostic mode (NBS versus selective screening), and the various treatment combinations used. CONCLUSIONS: NBS is an effective intervention to reduce time until diagnosis especially for LO patients and to prevent irreversible cerebral damage in GA1 and MMA-Cbl(-). Huge diversity of therapeutic interventions hampers our understanding of optimal treatment.
BACKGROUND AND AIM: To describe current diagnostic and therapeutic strategies in organic acidurias (OADs) and to evaluate their impact on the disease course allowing harmonisation. METHODS: Datasets of 567 OAD patients from the E-IMD registry were analysed. The sample includes patients with methylmalonic (MMA, n = 164), propionic (PA, n = 144) and isovaleric aciduria (IVA, n = 83), and glutaric aciduria type 1 (GA1, n = 176). Statistical analysis included description and recursive partitioning of diagnostic and therapeutic strategies, and odds ratios (OR) for health outcome parameters. For some analyses, symptomatic patients were divided into those presenting with first symptoms during (i.e. early onset, EO) or after the newborn period (i.e. late onset, LO). RESULTS:Patients identified by newborn screening (NBS) had a significantly lower median age of diagnosis (8 days) compared to the LO group (363 days, p < 0.001], but not compared to the EO group. Of all OAD patients 71 % remained asymptomatic until day 8. Patients with cobalamin-nonresponsive MMA (MMA-Cbl(-)) and GA1 identified by NBS were less likely to have movement disorders than those diagnosed by selective screening (MMA-Cbl(-): 10 % versus 39 %, p = 0.002; GA1: 26 % versus 73 %, p < 0.001). For other OADs, the clinical benefit of NBS was less clear. Reported age-adjusted intake of natural protein and calories was significantly higher in LO patients than in EO patients reflecting different disease severities. Variable drug combinations, ranging from 12 in MMA-Cbl(-) to two in isovaleric aciduria, were used for maintenance treatment. The effects of specific metabolic treatment strategies on the health outcomes remain unclear because of the strong influences of age at onset (EO versus LO), diagnostic mode (NBS versus selective screening), and the various treatment combinations used. CONCLUSIONS: NBS is an effective intervention to reduce time until diagnosis especially for LO patients and to prevent irreversible cerebral damage in GA1 and MMA-Cbl(-). Huge diversity of therapeutic interventions hampers our understanding of optimal treatment.
Authors: V Reid Sutton; Kimberly A Chapman; Andrea L Gropman; Erin MacLeod; Kathy Stagni; Marshall L Summar; Keiko Ueda; Nicholas Ah Mew; Jill Franks; Eddie Island; Dietrich Matern; Loren Peña; Brittany Smith; Tina Urv; Charles Venditti; Anupam Chakarapani Journal: Mol Genet Metab Date: 2011-09-10 Impact factor: 4.797
Authors: Krista Viau; Sharon L Ernst; Rena J Vanzo; Lorenzo D Botto; Marzia Pasquali; Nicola Longo Journal: Mol Genet Metab Date: 2012-06-09 Impact factor: 4.797
Authors: Stefan Kölker; Sven F Garbade; Cheryl R Greenberg; James V Leonard; Jean-Marie Saudubray; Antonia Ribes; H Serap Kalkanoglu; Allan M Lund; Begoña Merinero; Moacir Wajner; Mónica Troncoso; Monique Williams; John H Walter; Jaume Campistol; Milagros Martí-Herrero; Melissa Caswill; Alberto B Burlina; Florian Lagler; Esther M Maier; Bernd Schwahn; Aysegul Tokatli; Ali Dursun; Turgay Coskun; Ronald A Chalmers; David M Koeller; Johannes Zschocke; Ernst Christensen; Peter Burgard; Georg F Hoffmann Journal: Pediatr Res Date: 2006-04-26 Impact factor: 3.756
Authors: Stefan Kölker; S P Nikolas Boy; Jana Heringer; Edith Müller; Esther M Maier; Regina Ensenauer; Chris Mühlhausen; Andrea Schlune; Cheryl R Greenberg; David M Koeller; Georg F Hoffmann; Gisela Haege; Peter Burgard Journal: Mol Genet Metab Date: 2012-04-04 Impact factor: 4.797
Authors: Stefan Kölker; Sven F Garbade; Nikolas Boy; Esther M Maier; Thomas Meissner; Chris Mühlhausen; Julia B Hennermann; Thomas Lücke; Johannes Häberle; Jochen Baumkötter; Wolfram Haller; Edith Muller; Johannes Zschocke; Peter Burgard; Georg F Hoffmann Journal: Pediatr Res Date: 2007-09 Impact factor: 3.756
Authors: Sarah C Grünert; Stephanie Müllerleile; Linda De Silva; Michael Barth; Melanie Walter; Kerstin Walter; Thomas Meissner; Martin Lindner; Regina Ensenauer; René Santer; Olaf A Bodamer; Matthias R Baumgartner; Michaela Brunner-Krainz; Daniela Karall; Claudia Haase; Ina Knerr; Thorsten Marquardt; Julia B Hennermann; Robert Steinfeld; Skadi Beblo; Hans-Georg Koch; Vassiliki Konstantopoulou; Sabine Scholl-Bürgi; Agnes van Teeffelen-Heithoff; Terttu Suormala; Wolfgang Sperl; Jan P Kraus; Andrea Superti-Furga; Karl Otfried Schwab; Jörn Oliver Sass Journal: Orphanet J Rare Dis Date: 2013-01-10 Impact factor: 4.123
Authors: Roland Posset; Sven F Garbade; Nikolas Boy; Alberto B Burlina; Carlo Dionisi-Vici; Dries Dobbelaere; Angeles Garcia-Cazorla; Pascale de Lonlay; Elisa Leão Teles; Roshni Vara; Nicholas Ah Mew; Mark L Batshaw; Matthias R Baumgartner; Shawn E McCandless; Jennifer Seminara; Marshall Summar; Georg F Hoffmann; Stefan Kölker; Peter Burgard Journal: J Inherit Metab Dis Date: 2019-01 Impact factor: 4.982
Authors: Péter Monostori; Glynis Klinke; Sylvia Richter; Ákos Baráth; Ralph Fingerhut; Matthias R Baumgartner; Stefan Kölker; Georg F Hoffmann; Gwendolyn Gramer; Jürgen G Okun Journal: PLoS One Date: 2017-09-15 Impact factor: 3.240
Authors: Femke Molema; Diego Martinelli; Friederike Hörster; Stefan Kölker; Trine Tangeraas; Barbara de Koning; Carlo Dionisi-Vici; Monique Williams Journal: J Inherit Metab Dis Date: 2020-10-29 Impact factor: 4.982